Trials / Unknown
UnknownNCT03271073
A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
A Exploratory Study of Apatinib in Combination With S1 in Patients With Advanced Gastric Evaluating the Efficacy and Safety
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib showed good safety and efficacy as third-line therapy for advanced gastric cancer.We conducted this trial to investigate the safety and efficacy of apatinib combined with S1 after failure of first-line chemotherapy in advanced gastric cancer or gastroesophageal junction carcinoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2018-07-31
- Completion
- 2019-01-31
- First posted
- 2017-09-01
- Last updated
- 2017-09-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03271073. Inclusion in this directory is not an endorsement.